Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.

GlobeNewsWire • Dec 12, 2025

Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Seeking Alpha • Dec 8, 2025

Alector to Participate in the Bank of America CNS Therapeutics Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET.

GlobeNewsWire • Dec 1, 2025

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire • Nov 26, 2025

Alector Stock Plummets 63% in a Month: Here's What You Need to Know

ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.

Zacks Investment Research • Nov 18, 2025

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's disease; both advancing toward IND-enabling studies

GlobeNewsWire • Nov 6, 2025

Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.43 per share a year ago.

Zacks Investment Research • Nov 7, 2025

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 29, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Alector, Inc. ("Alector" or the "Company") (NASDAQ: ALEC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Oct 28, 2025

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD- GRN ).

Benzinga • Oct 22, 2025